- United States
- /
- Medical Equipment
- /
- NYSE:ENOV
Enovis (ENOV): Assessing Valuation After a 12% One-Month Share Price Decline
Reviewed by Simply Wall St
See our latest analysis for Enovis.
Enovis’s share price has not only retreated sharply over the last month but has also shown a clear loss of momentum, with a year-to-date share price return of -36.7% and a 12-month total shareholder return of -39.6%. After this slide, investors appear cautious, potentially reassessing both growth potential and perceived risks.
If you’re weighing your next move, now could be the perfect time to broaden your search and discover See the full list for free.
This sharp decline raises a key question for investors: Is Enovis now trading below its true value, or has the market simply adjusted to the company’s financial outlook, leaving little room for upside?
Most Popular Narrative: 43.5% Undervalued
With Enovis trading at $28.06, the prevailing narrative suggests the fair value is $49.67. This creates a significant gap between current market pricing and where analysts believe the stock could trade based on fundamentals and future growth potential. This invites a closer look at the catalysts supporting this view.
Ongoing geographic expansion and integration of recent acquisitions (especially the Lima shoulder portfolio) have significantly increased cross-selling opportunities and market access. These factors are driving the sales mix toward higher-growth and higher-margin segments, with further margin and earnings improvement expected in coming quarters from operational synergies.
Want to see what’s fueling this significant valuation gap? The drivers include ambitious growth forecasts and a roadmap aimed at turning losses into higher earnings. Learn more about the aggressive assumptions and margin targets that are shaping this compelling fair value projection.
Result: Fair Value of $49.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ongoing integration challenges and potential delays in new technology launches could quickly undermine the optimistic outlook for Enovis’s future earnings and margins.
Find out about the key risks to this Enovis narrative.
Build Your Own Enovis Narrative
If you want to dive deeper into the numbers or chart your own perspective, you can build your take on Enovis’s outlook in just a few minutes. Do it your way
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Enovis.
Looking for More Investment Ideas?
Ready to level up your portfolio? Now’s your opportunity to find outstanding stocks and trends that others could miss if they wait too long.
- Boost your returns by tapping into these 870 undervalued stocks based on cash flows, packed with companies trading below their true value. This can help you spot tomorrow’s winners today.
- Secure reliable income streams. Start researching these 16 dividend stocks with yields > 3% that consistently deliver attractive yields above the market average for stress-free earning potential.
- Capture the upside of the AI revolution with these 24 AI penny stocks, featuring trailblazers at the forefront of artificial intelligence advancements and industry disruption.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Enovis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NYSE:ENOV
Enovis
Operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally.
Undervalued with moderate growth potential.
Similar Companies
Market Insights
Community Narratives

